Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 97.00 | |
10 mg | In stock | $ 155.00 | |
25 mg | In stock | $ 322.00 | |
50 mg | In stock | $ 472.00 | |
100 mg | In stock | $ 693.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 113.00 |
Description | Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC. |
Targets&IC50 | EGFR (WT):689 nM (GI50), EGFR (L858R/T790M):5 nM (GI50), EGFR (del19):10 nM (GI50) |
In vitro | CK-101 specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward WT EGFR. It selectively inhibits cell proliferation of cell lines expressing both the activating (HCC827, IC50 <15 nM) and resistance mutations (NCI-H1975, IC50 <5 nM). |
In vivo | CK-101 significantly inhibits tumor growth in EGFR-mutated NSCLC tumor xenograft models, with no activity in the WT EGFR tumor xenograft model. |
Synonyms | CK-101, EGFR-IN-3, RX-518 |
Molecular Weight | 530.57 |
Formula | C29H28F2N6O2 |
CAS No. | 1660963-42-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 120 mg/mL (226.18 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olafertinib 1660963-42-7 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR RX 518 CK-101 EGFR-IN-3 CK 101 Inhibitor ErbB-1 Epidermal growth factor receptor CK101 RX-518 NSCLC HER1 RX518 inhibit inhibitor